Familial chylomicronaemia syndrome (LPL deficiency) OMIM 238600

In Familial chylomicronaemia syndrome (LPL, OMIM 238600), the master switch sits on the ↑ UP branch (cited role × mechanism, below); the healthy state is the ON well. The forced corrective direction is to raise s toward ON branch (polarity: clear). Classification: ✓ Recovers an existing standard. Direction only — no dose, no efficacy magnitude.

The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.4437, γ 1.3322, spinodal 0.5918). The corrective direction is an interpretation of the model (a code output whose sign follows from the cited lesion role and mechanism); the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.

The emergence switch

The switch for Familial chylomicronaemia syndrome is an R19 double-well emerged from the real proximal-promoter DNA of LPL. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.

emergent axis: ↑ UP (cited role × mechanism)
healthy branch: ON
lesion: LOF_null
γ (stiffness): 1.3322
barrier: 0.4437
spinodal: 0.5918
s_on / s_off: 1.1542 / -1.1542
fragility: 0.73
corrective polarity: clear
forced direction: raise s toward ON branch

Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically plausible (barrier 0.4437 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.

The derived corrective lever

The cusp forces a corrective direction: raise s toward ON branch. This is the load-bearing output of the framework — an interpretation of the model (code output, not a forced biological fact), and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).

h-restore (drive modulator)sign: decreasegeometric rank 0.73

Mechanism. remove / oppose the drive (clear the accumulating load that pins the disease branch)

Applies to. allele-agnostic (downstream/environmental tilt)

favoured when the switch is fragile -- a small drive shift recrosses the fold

Falsifier. If clearing/opposing the accumulating APOC3 does NOT relieve the disease branch in a LPL model, the h-restore(clear) lever is refuted for this axis.

gamma-restore (stabiliser / chaperone)sign: Nonegeometric rank 0.00

Mechanism. N/A

Applies to. none (honest exclusion)

EXCLUDED: null allele -- no product to stiffen

Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual LPL allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.

Agents mapped onto the lever

✓ Agreement with established practice. The corrective direction derived here (raise s toward ON branch) independently matches an agent already in clinical use for this disease: hepatocyte-targeted APOC3 antisense oligonucleotide (olezarsen); APOC3 antisense oligonucleotide (volanesorsen). The geometry recovered known medicine — this is a consistency check with established practice (partly by construction, since the corrective sign follows from the cited lesion class), not a new treatment claim by this kit.

Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
agent (class)	dir.	status	phase	map
hepatocyte-targeted APOC3 antisense oligonucleotide (olezarsen) Stroes 2024 (BALANCE, olezarsen in FCS); olezarsen (Tryngolza) FDA Dec 2024, EMA 2025 -- first therapy specifically approved for FCS	decrease	approved	4	✓ in use
APOC3 antisense oligonucleotide (volanesorsen) Witztum 2019 NEJM 381:531 (APPROACH, volanesorsen in FCS); volanesorsen (Waylivra) EMA 2019	decrease	approved	4	✓ in use
APOC3 small interfering RNA (plozasiran) Watts 2023/2024 (PALISADE, plozasiran APOC3 siRNA in FCS)	decrease	clinical	3	◇ in trials
LPL gene therapy (AAV1-LPL; alipogene tiparvovec was EMA-approved 2012, the first gene therapy approved in the West, since commercially withdrawn -- current programmes investigational) Gaudet 2013 Gene Ther 20:361 (alipogene tiparvovec / AAV1-LPL-S447X); Glybera EMA 2012 (withdrawn 2017 for commercial reasons)	decrease	investigational	2	◇ in trials

⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.

Direction-only candidate leads (corpus join)

Each lead is surfaced only because its known mechanism points the same way as the derived lever, and each comes with a source and a falsifier. None is a treatment.

volanesorsen✓ recovered standarddir: decrease · approved

Class. APOC3 antisense oligonucleotide (clearance enabler)

Mechanism. Volanesorsen lowers apolipoprotein C-III, an inhibitor of triglyceride clearance, enabling LPL-independent clearance routes so circulating triglyceride-rich chylomicrons fall despite the deficient lipoprotein lipase (LPL). Direction: decrease / clear the accumulating chylomicron triglyceride. Allele scope: agnostic -- engages an APOC3-dependent clearance route independent of the LPL variant. Pathway-specific (mapped to FCS via LPL only). The decrease direction recovers an approved triglyceride-lowering indication for this disease.

✓ This is a rediscovery. Volanesorsen (APOC3 antisense) is approved (EMA) for familial chylomicronaemia syndrome (triglyceride-lowering); the direction logic recovered an approved indication.

Safety (qualitative; no magnitude). platelet-count monitoring required on label (qualitative; no magnitude)

Falsifier. If volanesorsen (a pathway decrease agent) clearing/opposing the accumulating load does NOT relieve the UP disease branch in a LPL model, the h-restore(clear) direction is refuted for volanesorsen here.

Source: EMA label: volanesorsen (Waylivra), FCS; Witztum 2019 NEJM 381:531

⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.

Evidence & provenance

What is reproduced vs. cited for this page.
element	grade	basis
R19 switch & cusp geometry (this page)	code output	emerged from measured promoter γ of `LPL`; deterministic, 2×sha256 identical
corrective direction	interpretation	code output of the model: the sign follows from the cited lesion role × mechanism (which well the disease occupies); falsifiable (see lever falsifiers); magnitude [O]
mapped agents / leads	[O] open	direction-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude

Reading the agent column. VALIDATION SIGNAL (read: consistency with established practice, partly by construction, since the corrective sign follows from the cited lesion class) -- the agent is already approved / established standard for this disease, so the direction logic agrees with known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).